What question did this study set out to answer?

This study investigates the relationship between pretreatment immune-nutritional biomarkers and survival outcomes in locally advanced non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy.

August 2, 2026Open Access

Pretreatment prognostic nutritional index is associated with survival outcomes in locally advanced NSCLC treated with definitive chemoradiotherapy

SİSerdar İleriDiyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi STSezai TunçŞanlıurfa Mehmet Akif İnan Eğitim ve Araştırma Hastanesi OKOğur KarhanHarran University

Key Points

This study investigates the relationship between pretreatment immune-nutritional biomarkers and survival outcomes in locally advanced non-small cell lung cancer (NSCLC) patients treated with chemoradiotherapy.
Evaluated 102 patients with histologically confirmed NSCLC receiving definitive-intent chemoradiotherapy.
Calculated prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) from laboratory values.
Median follow-up duration was 56.4 months.
Low PNI (≤ 43.5) was associated with shorter progression-free survival (PFS) of 13.3 months compared to 19.4 months (HR, 1.99; 95% CI, 1.25–3.19; P = 0.003).
Overall survival (OS) was also shorter for low PNI (26.4 months) compared to high PNI (31.3 months; HR, 1.70; 95% CI, 1.04–2.79; P = 0.033).
In multivariable models, PNI remained a significant predictor of worse PFS and OS.

Abstract

Definitive chemoradiotherapy (CRT) remains a curative-intent treatment for unresectable or medically inoperable locally advanced non-small cell lung cancer (NSCLC), although outcomes vary substantially. This retrospective cohort study evaluated the association of pretreatment immune-nutritional biomarkers with survival in 102 patients with histologically confirmed NSCLC treated with definitive-intent CRT. Pretreatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and prognostic nutritional index (PNI), defined as 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (/mm³), were calculated from routine laboratory values. Median follow-up was 56.4 months. Median progression-free survival (PFS) and overall survival (OS) were 15.8 and 29.2 months, respectively. Using the OS-derived PNI cut-off of 43.5, low PNI was associated with shorter PFS (13.3 vs. 19.4 months; HR, 1.99; 95% CI, 1.25–3.19; P = 0.003) and OS (26.4 vs. 31.3 months; HR, 1.70; 95% CI, 1.04–2.79; P = 0.033). In multivariable models, PNI ≤ 43.5 remained independently associated with worse PFS and OS, whereas NLR and PLR were not associated with survival. Pretreatment PNI may support risk stratification before definitive CRT, but external validation is required.

Ask AI

Helpful

Bookmark

View Full Paper